Time to rethink haemoglobin threshold guidelines in sickle cell disease.

Authors:
Ballas SK; Kuypers FA; Gordeuk VR; Hankins JS; Thompson AA and 1 more

Journal:
Br J Haematol

Publication Year: 2021

DOI:
10.1111/bjh.17578

PMCID:
PMC9292304

PMID:
34131897

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Br J Haematol

Abbreviation: Br J Haematol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Hematology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Accumulation of foamy macrophages in the bone marrow following chronic intravenous drug use.
Kyla Y; Penelope K; Kerry BM and 1 more (2022) - Transparency Score: 1/6
Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with elt…
Al-Samkari H; Jiang D; Gernsheimer T and 5 more (2022) - Transparency Score: 3/6
Antithrombin-III mitigates thrombin-mediated endothelial cell contraction and sickle red blood cell…
Wulftange WJ; Kucukal E; Man Y and 10 more (2022) - Transparency Score: 4/6
A survey on thromboprophylaxis and coagulation assessment in children and young adults with acute l…
Andersson NG; Rathe M; Mølle I and 12 more (2022) - Transparency Score: 3/6
BCR::ABL1 transcripts and clinical outcome - interrogating the technique.
Branford S. (2022) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
2/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflicts of interest SKB: Novartis, speakers' bureau and honoraria; Pfizer, Global Blood Therapeutics, Modus Therapeutics AB, Novartis, consultant; FAK: Global Blood Therapeutics, consultant; Global Blood Therapeutics, Agios, FORMA, CERUS, research funding; VRG: Global Blood Therapeutics, Emmaus, Incyte, Novartis, research funding; Modus Therapeutics, Global Blood Therapeutics, Emmaus, consultant; JSH: Global Blood Therapeutics, consultant; MJH Life Sciences, Vindico Medical Education, honoraria; Global Blood Therapeutics, Novartis, research funding; AAT: Agios, Beam, Celgene, bluebird bio, consulting; Baxalta, BioMarin, bluebird bio, Celgene, Novartis, research funding; EV: Global Blood Therapeutics, consultant; Agios, Pfizer, research funding."

Evidence found in paper:

"Funding information Global Blood Therapeutics provided funding for editorial services."

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025